



GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/24/000009

To,

M/s. AstraZeneca Pharma India Limited,
Block N1, 12th Floor Manyata Embassy,
Business Park, Rachenahalli Outer Ring Road,
Bangalore, Karnataka (India) – 560045.

Sir,

With reference to your application No. GCT/CT04/FF/2024/41468 (GCT/9/24) dated 14.01.2024, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria).”** Protocol No.: **D4325C00010, CSP Version No. 1.0 dated 27 Aug 2023 with a total of up-to 45 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- (ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

File No. CT/9/24-DCG(I)

- (iv) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

File No. CT/9/24-DCG(I)

- (xviii) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- (xix) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD
CONTROL, email=rajeev.singh@cds.gov.in, cn=RAJEEV
SINGH RAGHUVANSHI
2.5.4.20=f2d718991c0981bb5a263a4a73d025ff4b11
b680a91f08773480400a43ee3e3e1b,
postalCode=110002, st=Delhi,
serialNumber=657f5e47d940985d8f03bdc902d0e1fe
73cfa12a1a126ea94fa5701124a19013, cn=RAJEEV
SINGH RAGHUVANSHI
Date: 2024.08.16 12:53:46 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

FORM CT-06
(See rules 22,25,26,29 and 30)
**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s. AstraZeneca Pharma India Limited, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore, Karnataka (India) - 560045** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.: D4325C00010, CSP Version No. 1.0 dated 27 Aug 2023** in the below mentioned clinical trial sites [As per Annexure].

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

RAJEEV SINGH
RAGHUVANSHI
Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION,
2.5.4.20=42d7189b1c0981b55a26344a73d029f4b11b680a91f
087734804004e3e391fb, postalCode=110002, st=Delhi,
serialNumber=6575e47d940985d8f03bd902d0e1fe73cfa12a
1a126ea94fa5701124a19013, cn=RAJEEV SINGH
RAGHUVANSHI
Date: 2024.08.16 12:54:04 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Zibotentan 0.25mg+ Dapagliflozin 10mg Zibotentan 0.75mg + Dapagliflozin 10mg
Therapeutic class:	Endothelin Receptor antagonist and SGLT2 inhibitor Endothelin Receptor antagonist and SGLT2 inhibitor
Dosage form:	Tablets Tablets
Composition:	Zibotentan =0.2500 milligram (mg) In House Specification Active Dapagliflozin propanediol =12.3000 milligram (mg) In House Specification Active Hydroxypropyl cellulose =7.5000 milligram (mg) U.S.P.,J.P., Ph.Eur Inactive Low-substituted hydroxypropyl cellulose =10.0000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Magnesium stearate =2.5000 milligram (mg) U.S.P. Inactive Mannitol,

File No. CT/9/24-DCG(I)

	<p>SD200 =117.0000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Mannitol, 50c =50.2000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Microcrystalline cellulose =50.0000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Opadry beige =8.7500 milligram (mg) Manufacturer Specification Inactive Purified water =1.0000 q.s. U.S.P. Inactive</p> <p>Zibotentan =0.7500 milligram (mg) In House Specification Active Dapagliflozin propanediol =12.3000 milligram (mg) In House Specification Active Hydroxypropyl cellulose =7.5000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Low-substituted hydroxypropyl cellulose =10.0000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Magnesium stearate =2.5000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Mannitol, SD200 =117.0000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Mannitol, 50c =50.1000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Microcrystalline cellulose =50.0000 milligram (mg) U.S.P.,J.P.,Ph.Eur Inactive Opadry beige =8.7500 milligram (mg) Manufacturer Specification Inactive Purified water =1.0000 q.s. U.S.P.,Ph.Eur Inactive</p>
Indications:	<p>Adult participants with CKD and high proteinuria, with or without T2DM</p> <p>Adult participants with CKD and high proteinuria, with or without T2DM</p>

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Max Super Speciality Hospital, Saket (West Block), (A unit of Max Healthcare Institute Limited), 1 Press Enclave Road, Saket, New Delhi - 110017	Max Healthcare Ethics Committee, West block, Near MS Office Max Super Speciality Hospital, Saket (A unit of Max Healthcare Institute Limited), 1, Press enclave Road, Saket, New Delhi, 110017 ECR/118/Inst/DL/2013/RR-19	Dr Dinesh Khullar
2.	Muljibhai Patel Society for Research in Nephro-Urology, c/o, Muljibhai Patel Urological Hospital, Dr. Virendra Desai Road, Nadiad, Gujarat - 387001	Muljibhai Patel Society for Research in Nephro-Urology Ethics Committee, Muljibhai Patel Urological Hospital, Dr Virendra Desai Road, Nadiad, Kheda, Gujarat – 387001 ECR/276/Muljibhai/Inst/GJ/2013/RR-19	Dr Hardik Baldevbhai Patel

File No. CT/9/24-DCG(I)

3.	BGS Gleneagles Global Hospitals, No. 67, Uttarahalli Main road, Kengeri, Bengaluru - 560060	Institutional Ethics Committee, BGS Global Hospitals, BGS Health and Education City, 67, Uttarahalli Main Road, Kengeri, Bangalore Urban, Karnataka, 560060 ECR/128/Inst/KA/2013/RR-19	Dr Anil Kumar BT
4.	KLES Dr Prabhakar Kore Hospital & Medical Research Centre, Nehrunagar, Belgavi - 590010, Karnataka	Institutional Ethics Committee, KLE University, KLE Dr.PK Hospital and MRC, Nehru Nagar, Belagavi (Belgaum), Karnataka - 590010 ECR/211/Inst/KA/2013/RR-19	Dr Ritesh Ramesh Vernekar
5.	Jawaharlal Institute of Postgraduate and Medical Education, Research JIPMER, Super Speciality Block, Dhanvantari Nagar, Gorimedu, Puducherry Puducherry - 605006	IEC Intervention Studies, JIPMER (Jawaharlal Institute of Postgraduate and Medical Education & Research), Dhanvantari Nagar, Puducherry - 605006 ECR/342/Inst/PY/2013/RR-19	Dr Sreejith Parameswaran
6.	All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110029	Institute Ethics Committee, All India Institute of Medical Sciences, Old OT Block, Room No.102, Ansari Nagar, New Delhi, Delhi - 110029 ECR/538/Inst/DL/2014/RR-20	Dr Arunkumar Subbiah
7.	SMS Superspeciality Hospital, Attached to SMS Medical College, Vivekananda Marg, C-Scheme, Jaipur-302001, Rajasthan	Ethics Committee, SMS Medical College and Attached Hospitals, JLN Marg, Jaipur, Rajasthan, 302004 ECR/26/Inst/RJ/2013/RR-19	Dr Dhananjai Agrawal
